THROMBOGENICS

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1985-01-01

Employees: -

Market Cap: -

Website: http://www.thrombogenics.com

Clinical Trials

The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

Phase 2

Completed

Conditions: Vitrectomy

Interventions: Drug: ocriplasmin

First Posted Date: 2010-07-09

Last Posted Date: 2014-12-17

Lead Sponsor: ThromboGenics

Target Recruit Count: 38

Registration Number: NCT01159665

Locations: 🇧🇪
University Hospital Leuven, Leuven, Belgium

Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion

Phase 2

Completed

Conditions: Focal Vitreomacular Adhesion

Interventions: Drug: Microplasmin

First Posted Date: 2010-01-25

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 17

Registration Number: NCT01055535

Locations: 🇧🇪
University Hospital Leuven, Leuven, Belgium

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy

Phase 2

Completed

Conditions: Vitrectomy

Interventions: Drug: Placebo
Drug: Ocriplasmin

First Posted Date: 2009-09-29

Last Posted Date: 2014-12-17

Lead Sponsor: ThromboGenics

Target Recruit Count: 24

Registration Number: NCT00986362

Locations: 🇺🇸
Associated Retina Consultants, Royal Oak,, Michigan, United States

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

Phase 2

Completed

Conditions: Exudative Age-Related Macular Degeneration
Focal Vitreomacular Adhesion

Interventions: Drug: Sham injection
Drug: Ocriplasmin

First Posted Date: 2009-06-04

Last Posted Date: 2014-12-17

Lead Sponsor: ThromboGenics

Target Recruit Count: 100

Registration Number: NCT00913744

Locations: 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸
Retinal Consultants of Houston,, Houston,, Texas, United States
🇬🇧
Moorfields Eye Hospital, London, United Kingdom

and more 24 locations

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

Phase 3

Completed

Conditions: Vitreomacular Adhesion

Interventions: Drug: Placebo
Drug: Ocriplasmin 125µg

First Posted Date: 2008-11-26

Last Posted Date: 2014-12-17

Lead Sponsor: ThromboGenics

Target Recruit Count: 326

Registration Number: NCT00798317

Locations: 🇺🇸
Retina Specialists, Pensacola, Florida, United States
🇺🇸
Black Hils regional Eye Institute, Rapid City, South Dakota, United States
🇺🇸
Scheie Eye Institute, Penn Eye Care, Philadelphia,, Pennsylvania, United States

and more 45 locations

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

Phase 2

Completed

Conditions: Total Knee Replacement Surgery

Interventions: Drug: TB-402
Drug: Enoxaparin

First Posted Date: 2008-11-19

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 316

Registration Number: NCT00793234

Locations: 🇺🇦
Cherkasska Regional Hospital. Department of Orthopedics and Traumatology., Cherkassy, Ukraine
🇷🇺
Saint Petersburg State Healthcare Institution "Municipal Multi-Speciality Hospital No. 2", Saint Petersburg, Russian Federation
🇺🇦
Ivano-Frankіvsk Regional Clinical Hospital, Department of ortopedics and traumatology., Ivano-Frankivsk, Ukraine

and more 32 locations

Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

Phase 3

Completed

Conditions: Vitreomacular Adhesion

Interventions: Drug: Placebo
Drug: 125 µg Ocriplasmin

First Posted Date: 2008-10-29

Last Posted Date: 2014-12-17

Lead Sponsor: ThromboGenics

Target Recruit Count: 326

Registration Number: NCT00781859

Locations: 🇺🇸
Retina Vitreous Associate Medical Group, Beverly Hills, California, United States
🇺🇸
VMR Institute, Huntington Beach, California, United States
🇺🇸
Southern California Desert Retina Consultants, Palm Springs, California, United States

and more 38 locations

Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects

First Posted Date: 2008-02-20

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 15

Registration Number: NCT00618579

Locations: 🇩🇰
Cyncron CRU, Copenhagen, Denmark

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402

First Posted Date: 2008-02-11

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 12

Registration Number: NCT00612417

Locations: 🇩🇰
Cyncron CRU, Copenhagen, Denmark

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TB-402
Drug: Placebo

First Posted Date: 2008-02-11

Last Posted Date: 2014-04-07

Lead Sponsor: ThromboGenics

Target Recruit Count: 56

Registration Number: NCT00612196

Locations: 🇩🇰
Cyncron Clinical Research Unit, Copenhagen, Denmark

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy